

PRIOR AUTHORIZATION POLICY

POLICY: Oncology (Injectable) – Polivy Prior Authorization Policy

- Polivy® (polatuzumab vedotin-piiq intravenous infusion – Genentech)

REVIEW DATE: 06/26/2024

OVERVIEW

Polivy, a CD79b-directed antibody-drug conjugate, is indicated:¹

- For the treatment of relapsed or refractory **diffuse large B-cell lymphoma** (DLBCL), not otherwise specified, in combination with bendamustine and a rituximab product in adults after at least two prior therapies.
- For previously untreated **DLBCL**, not otherwise specified or **high-grade B-cell lymphoma**, in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) in adults with an International Prognostic Index (IPI) score of ≥ 2 .

Guidelines

The National Comprehensive Cancer Network (NCCN) guidelines on **B-Cell Lymphomas** (version 2.2024 – April 30, 2024) recommend Polivy for the second-line or subsequent treatment of DLBCL, follicular lymphoma, histologic transformation of indolent lymphoma to DLBCL, HIV-related B-cell lymphoma, post-transplant lymphoproliferative disorders, and high-grade B-cell lymphoma.^{2,3} In addition, NCCN recommends Polivy for the first-line treatment of DLBCL in combination with R-CHP for patients with IPI ≥ 2 .

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Polivy. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Polivy as well as the monitoring required for adverse events and long-term efficacy, approval requires Polivy to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Polivy is recommended in those who meet one of the following:

FDA-Approved Indications

1. **Diffuse Large B-Cell Lymphoma.** Approve for 6 months if the patient meets ALL of the following (A, B, and C):

Note: Includes histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma.

A) Patient is ≥ 18 years of age; AND

B) Patient meets ONE of the following (i or ii):

i. Patient meets BOTH of the following (a and b):

a) Patient has an International Prognostic Index score of ≥ 2 ; AND

b) Polivy is used as first-line therapy; OR

06/26/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

- ii. Patient has been treated with at least one prior chemotherapy regimen; AND
Note: Examples of chemotherapy regimens include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) plus rituximab.
 - C) Polivy is prescribed by or in consultation with an oncologist.
2. **High-Grade B-Cell Lymphoma.** Approve for 6 months if the patient meets ALL of the following (A, B, and C):
- A) Patient is ≥ 18 years of age; AND
 - B) Patient meets ONE of the following (i or ii):
 - i. Patient meets BOTH of the following (a and b):
 - a) Patient has an International Prognostic Index score of ≥ 2 ; AND
 - b) Polivy is used as first-line therapy; OR
 - ii. Patient has been treated with at least one prior chemotherapy regimen; AND
Note: Examples of chemotherapy regimens include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) plus rituximab.
 - C) Polivy is prescribed by or in consultation with an oncologist.

Other Uses with Supportive Evidence

3. **B-Cell Lymphoma.** Approve for 6 months if the patient meets ALL of the following (A, B, and C):
Note: Examples include HIV-related B-cell lymphoma and post-transplant lymphoproliferative disorders.
- A) Patient is ≥ 18 years of age; AND
 - B) Patient has been treated with at least one prior chemotherapy regimen; AND
Note: Examples of chemotherapy regimens include CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) plus rituximab or Gazyva (obinutuzumab intravenous infusion), CVP (cyclophosphamide, vincristine, prednisone) plus rituximab or Gazyva, or lenalidomide plus rituximab.
 - C) Polivy is prescribed by or in consultation with an oncologist.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Polivy is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Polivy™ intravenous infusion [prescribing information]. South San Francisco, CA: Genentech; April 2023.
2. The NCCN B-Cell Lymphomas Clinical Practice Guidelines in Oncology (version 2.2024 – April 30, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 17, 2024.
3. The NCCN Drugs & Biologics Compendium. © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 17, 2024. Search term: polatuzumab.